



Publications

CYP2D6-Opioids Clinical Decision Support

Last Updated August 17, 2018

1. Brixner D, Biltaji E, Bress A, Unni S, Ye X, Mamiya T, Ashcraft K, Biskupiak J. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. *J Med Econ*. 2016;19(3):213-28. doi: 10.3111/13696998.2015.1110160. PubMed PMID: 26478982.
2. Gammal RS, Crews KR, Haidar CE, Hoffman JM, Baker DK, Barker PJ, Estep JH, Pei D, Broeckel U, Wang W, Weiss MJ, Relling MV, Hankins J. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. *Pediatrics*. 2016 Jul;138(1). pii: e20153479. doi: 10.1542/peds.2015-3479. PubMed PMID: 27335380; PubMed Central PMCID: PMC4925073.
3. Ji Y, Skierka JM, Blommel JH, Moore BE, VanCuyk DL, Bruflat JK, Peterson LM, Veldhuizen TL, Fadra N, Peterson SE, Lagerstedt SA, Train LJ, Baudhuin LM, Klee EW, Ferber MJ, Bielinski SJ, Caraballo PJ, Weinshilboum RM, Black JL 3rd. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. *J Mol Diagn*. 2016 May;18(3):438-45. doi: 10.1016/j.jmoldx.2016.01.003. PubMed PMID: 26947514; PubMed Central PMCID: PMC4851731.
4. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, Hunkler RJ, Klein TE, Evans WE, Relling MV. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. *Annu Rev Pharmacol Toxicol*. 2015;55:89-106. doi: 10.1146/annurev-pharmtox-010814-124835. Review. PubMed PMID: 25292429; PubMed Central PMCID: PMC4607278.
5. Caraballo PJ, Parkulo M, Blair D, Elliott M, Schultz C, Sutton J, Rao P, Bruflat J, Bleimeyer R, Crooks J, Gabrielson D, Nicholson W, Rohrer Vitek C, Wix K, Bielinski SJ, Pathak J, Kullo I. Clinical Decision Support to Implement CYP2D6 DrugGene Interaction. *Stud Health Technol Inform*. 2015;216:946. PubMed PMID: 26262248.
6. Hoffman JM, Haidar CE, Wilkinson MR, Crews KR, Baker DK, Kornegay NM, Yang W, Pui CH, Reiss UM, Gaur AH, Howard SC, Evans WE, Broeckel U, Relling MV. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. *Am J Med Genet C Semin Med Genet*. 2014 Mar;166C(1):45-55. doi: 10.1002/ajmg.c.31391. PubMed PMID: 24619595; PubMed Central PMCID: PMC4056586.
7. Bell GC, Crews KR, Wilkinson MR, Haidar CE, Hicks JK, Baker DK, Kornegay NM, Yang W, Cross SJ, Howard SC, Freimuth RR, Evans WE, Broeckel U, Relling MV, Hoffman JM. Development and use of active clinical decision support for preemptive pharmacogenomics. *J Am Med Inform Assoc*. 2014 Feb;21(e1):e93-9. doi:10.1136/amiajnl-2013-001993. PubMed PMID: 23978487; PubMed Central PMCID: PMC3957400.
8. Bielinski SJ, Olson JE, Pathak J, Weinshilboum RM, Wang L, Lyke KJ, Ryu E, Targonski PV, Van Norstrand MD, Hathcock MA, Takahashi PY, McCormick JB, Johnson KJ, Maschke KJ, Rohrer Vitek CR, Ellingson MS, Wieben ED, Farrugia G, Morrisette JA, Kruckeberg KJ, Bruflat JK, Peterson LM, Blommel JH, Skierka JM, Ferber MJ, Black JL, Baudhuin LM, Klee EW, Ross JL, Veldhuizen TL, Schultz CG, Caraballo PJ, Freimuth RR, Chute CG, Kullo IJ. Preemptive

genotyping for personalized medicine: design of the right drug, right dose, right time -using genomic data to individualize treatment protocol. *Mayo Clin Proc.* 2014 Jan;89(1):25-33. doi: 10.1016/j.mayocp.2013.10.021. PubMed PMID: 24388019; PubMed Central PMCID: PMC3932754.